Phase I and II clinical trials treating patients with idiopathic pulmonary fibrosis using a novel PDE4B inhibitor, BI 1015550, have shown promising results (Richeldi et al., 2022). This evidence concerns the gene PDE4B and idiopathic pulmonary fibrosis.